The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis

Table 3

Survival outcomes of all the included studies.

Trial name	Test vs. control	OS				Median PFS
		Test (%)	Control (%)	HR (95% CI)	value	Test (mo)	Control (mo)	HR (95% CI)	value
STAMPEDE	ABI + PRE + ADT vs. Placebos + ADT	83	73	0.63 (0.52–0.76)	<0.001	43.9	30.0	0.29 (0.25–0.34)	<0.001
LATITUDE	ABI + PRE + ADT vs. Placebos + ADT	66	49	0.62 (0.51–0.76)	<0.001	33.0	14.8	0.47 (0.39–0.55)	<0.001
TITAN	APA + ADT vs. Placebos + ADT	82.4	73.5	0.67 (0.51–0.89)	0.005	NR	NR	0.49 (0.40–0.61)	NR
ARCHES	ENZ + ADT vs. Placebos + ADT	NR	NR	0.81 (0.53–1.25)	0.336	NR	19.0	0.39 (0.30–0.50)	<0.001
ENZAMET	ENZ + ADT vs. ADT	NR	NR	0.67 (0.52–0.86)	0.002	NR	NR	0.40 (0.33–0.49)	<0.001
ARASENS	DAR + DOC + ADT vs. Placebos + DOC + ADT	62.7	50.4	0.68 (0.57–0.80)	<0.001	51.2	39.7	0.61 (0.52–0.72)	<0.001

OS, overall survival; PFS, progression-free survival; ABI, abiraterone; PRE, prednisolone; ADT, androgen-deprivation therapy; ENZ, enzalutamide; APA, apalutamide; DAR, darolutamide; DOC, docetaxel; NR, not reported.